ÖйúPÕ¾

Neurocysticercosis; Parasitic Brain Infections; Diagnosis; Treatment; Prevention; Neurological Health; Toxoplasmosis; Schistosomiasis; Praziquantel; Neuroimaging

Introduction

Neurocysticercosis, a significant parasitic infection of the central nervous system caused by the larval stage of the pork tapeworm Taenia solium, presents a substantial global health challenge, particularly in lower and middle-income countries. Recent scientific endeavors have focused on advancing its diagnosis, treatment, and prevention strategies. Newer diagnostic tools, such as serological assays and sophisticated neuroimaging techniques, are proving instrumental in facilitating earlier detection of this debilitating condition [1].

Treatment regimens for neurocysticercosis are continually being refined, with a growing emphasis on minimizing the parasitic burden and effectively managing inflammation to mitigate the risk of long-term neurological sequelae. Concurrently, public health initiatives that promote proper sanitation, food safety practices, and responsible animal husbandry are recognized as fundamental elements in disrupting the transmission cycle of this parasitic infection [1].

Research has also explored the efficacy and safety of combination therapies for neurocysticercosis, specifically evaluating the synergistic effects of albendazole and praziquantel in managing the disease. Such investigations aim to identify optimal treatment protocols tailored to individual patient characteristics and the specific lesion burden, thereby enhancing lesion resolution and reducing seizure frequency [2].

Beyond neurocysticercosis, other parasitic infections pose serious threats to neurological health, including Toxoplasma gondii encephalitis, a critical opportunistic infection commonly affecting immunocompromised individuals. Understanding the immunopathogenesis, particularly the role of T cell-mediated immunity, is crucial for managing this condition and improving patient outcomes through updated treatment strategies [3].

Cerebral schistosomiasis, a neglected tropical disease stemming from Schistosoma species, also contributes to neurological morbidity. Reviewing its epidemiology, clinical presentation, and diagnostic hurdles is essential for timely intervention, especially in endemic regions. Current therapeutic approaches, primarily praziquantel, alongside robust prevention strategies like mass drug administration, are vital for control [4].

The utility of advanced neuroimaging modalities, including MRI and PET scans, has been underscored in the diagnosis and characterization of parasitic brain infections. These techniques are invaluable in differentiating parasitic etiologies from inflammatory processes, thus guiding effective treatment planning and prognosis determination [5].

Epidemiological studies continue to shed light on the prevalence and clinical spectrum of parasitic infections like cysticercosis in various populations. Such research often employs serological markers and neuroimaging to assess disease burden, identify risk factors, and highlight the ongoing public health significance of these infections, emphasizing the need for targeted control measures [6].

The intricate relationship between parasitic infections and a spectrum of neurological disorders, ranging from meningitis and encephalitis to epilepsy, necessitates a comprehensive understanding. Identifying the various parasitic agents involved and addressing the associated diagnostic and therapeutic challenges are paramount for effective management in vulnerable populations [7].

Furthermore, the effectiveness and limitations of antiparasitic drugs like praziquantel in managing neurocysticercosis-associated epilepsy are subjects of ongoing investigation. Research in this area provides critical insights into optimal dosing, the potential for drug resistance, and the importance of long-term patient follow-up, especially in resource-limited settings [8].

Finally, the evolving landscape of neuroparasitic diseases, influenced by factors such as climate change, increased travel, and urbanization, presents emerging trends and public health challenges. A proactive approach, incorporating surveillance, early diagnosis, effective treatment, and a One Health perspective, is crucial for addressing these complex issues effectively [9].

Description

Neurocysticercosis, a prevalent parasitic infection of the central nervous system caused by the larval stage of the pork tapeworm *Taenia solium*, remains a significant global health concern, particularly in low- and middle-income countries. Recent advancements in its diagnosis, treatment, and prevention strategies have been highlighted. Newer diagnostic tools, including serological assays and advanced neuroimaging techniques, are improving early detection capabilities [1].

Treatment regimens are evolving, with a focus on reducing parasitic burden and managing inflammation to prevent long-term neurological sequels. Public health initiatives emphasizing proper sanitation, food safety, and animal husbandry are crucial for interrupting the transmission cycle of this parasitic infection [1].

Studies have investigated the efficacy and safety of combination therapies for neurocysticercosis, assessing the synergistic effect of albendazole and praziquantel. Findings suggest improved lesion resolution and reduced seizure frequency compared to monotherapy, underscoring the importance of tailored treatment protocols based on lesion burden and patient characteristics [2].

Beyond *Taenia solium*, other parasitic infections like *Toxoplasma gondii* encephalitis pose serious threats to neurological health, especially in immunocompromised individuals. Understanding the immunopathogenesis and host immune responses is vital for managing this opportunistic infection and improving patient outcomes through updated therapeutic strategies [3].

Cerebral schistosomiasis, a neglected tropical disease caused by *Schistosoma* species, can lead to significant neurological manifestations. Reviewing its epidemiology, clinical presentation, and diagnostic challenges is critical for early intervention, particularly in endemic areas. Current therapeutic interventions, primarily praziquantel, coupled with prevention strategies, are emphasized for control [4].

The role of advanced neuroimaging modalities, such as MRI and PET scans, is pivotal in identifying and characterizing parasitic brain infections. These techniques aid in differentiating various parasitic etiologies and inflammatory processes, thereby assisting in treatment planning and prognosis assessment [5].

Epidemiological research in urban settings has illuminated the prevalence and clinical spectrum of cysticercosis, including *Taenia solium* cysticercosis and its neurological complications, primarily epilepsy. Such studies employ serological markers and neuroimaging to assess disease burden and risk factors, reinforcing the public health importance of targeted interventions [6].

The complex interplay between parasitic infections and neurological disorders, including meningitis, encephalitis, and seizures, demands a thorough understanding. Identifying implicated parasitic agents and addressing diagnostic and therapeutic challenges are essential for effective management, especially in vulnerable populations requiring integrated strategies [7].

Research continues to explore the effectiveness and limitations of praziquantel in treating neurocysticercosis-associated epilepsy, providing insights into optimal dosing regimens and the emergence of drug resistance. Long-term follow-up and accessibility in resource-limited settings are also critical considerations [8].

Emerging trends in neuroparasitic diseases, influenced by environmental and socioeconomic factors, present ongoing public health challenges. Addressing these complex issues requires a comprehensive approach, encompassing surveillance, diagnosis, treatment, and a One Health perspective to combat the transmission and impact of these infections [9].

Conclusion

This collection of research highlights the significant impact of parasitic infections on neurological health. Neurocysticercosis, caused by *Taenia solium*, remains a major concern, with ongoing advancements in diagnosis and treatment, including combination therapies and improved imaging techniques. Other parasitic infections like toxoplasmosis and schistosomiasis also contribute to neurological morbidity, necessitating tailored management and prevention strategies. The effectiveness of antiparasitic drugs like praziquantel is being studied, alongside emerging challenges influenced by environmental and socioeconomic factors. A comprehensive understanding of the interplay between parasites and the nervous system, coupled with integrated public health measures, is crucial for combating these diseases globally.

References

1. Ahmed AE, Mostafa ME, Mohamed SA. (2023) .J Neuroinfect Dis 14:1-15.

   , ,

2. Hany RH, Nadia KI, Omar MK. (2022) .J Neuroinfect Dis 13:45-58.

   , ,

3. Fatma AS, Amr FM, Khaled SE. (2024) .J Neuroinfect Dis 15:112-125.

   , ,

4. Zeinab MA, Tarek AA, Salwa EM. (2021) .J Neuroinfect Dis 12:201-215.

   , ,

5. Karim SI, Noura HE, Ali MG. (2023) .J Neuroinfect Dis 14:150-162.

   , ,

6. Osama MZ, Sherif AE, Mona SA. (2022) .J Neuroinfect Dis 13:78-90.

   , ,

7. Aisha HG, Sameh MR, Yasser TS. (2024) .J Neuroinfect Dis 15:180-195.

   , ,

8. Mohamed AH, Rania FE, Gamal SE. (2021) .J Neuroinfect Dis 12:300-315.

   , ,

9. Hanaa MA, Walid KM, Eman AE. (2023) .J Neuroinfect Dis 14:250-265.

   , ,

10. Amal MO, Nabil SF, Ahmed AM. (2022) .J Neuroinfect Dis 13:350-365.

    , ,